|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
U.S. Government Expands Population Eligible to Receive Bavarian Nordic (BAVA.CO)'s Smallpox Vaccine in an Emergency
7/11/2012 9:25:25 AM
KVISTGAARD, Denmark, July 11, 2012 (GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. government has expanded the population that is eligible to receive its attenuated smallpox vaccine, IMVAMUNE(r), during an emergency. In the event of a public health emergency involving smallpox, the government may now authorize the use of IMVAMUNE(r) to protect individuals of all ages with HIV infection or atopic dermatitis (AD). Children, pregnant women, and nursing mothers with HIV or AD are eligible to receive IMVAMUNE(r), despite limited clinical data in these specific populations. Previously, only certain people with HIV were eligible.
|
|
|
|
|
|
|
|
|
|
|